Evergreening: A deceptive device in patent rights

Technology in Society

Volumn 32, Issue 4, 2010, Pages 324-330

  Dwivedi, Gaurav ^a   Hallihosur, Sharanabasava ^a   Rangan, Latha ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY GUWAHATI   (India)

Author keywords

Branding; Drugs; Evergreening; Generics drugs; Patents; Pharmaceuticals

Indexed keywords

BRANDING; DRUGS; EVERGREENING; GENERICS DRUGS; PATENTS; PHARMACEUTICALS;

DRUG PRODUCTS;

PATENTS AND INVENTIONS;

DRUG; FIRM SIZE; INNOVATION; MARKET SYSTEM; MONOPOLY; PHARMACEUTICAL INDUSTRY; STAKEHOLDER; STRATEGIC APPROACH;

EID: 78649866527     PISSN: 0160791X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.techsoc.2010.10.009     Document Type: Article

References (7)

1. Thomas A.F., Joel L. Linkage pharmaceutical evergreening in Canada and Australia. Australia and New Zealand Health Policy 2007, 4(8). See also. http://www.anzhealthpolicy.com/content/pdf/1743-8462-4-8.pdf.
2. Vasanthakumar N.B. Patent term extension strategies in the pharmaceutical industry. Pharmaceuticals Policy and Law 2005, 6:109-122.
3. Laurie L.H. The Orange Book. Nature Review/Drug Discovery 2005, 4. http://www.nature.com/nrd/journal/v4/n8/pdf/nrd1804.pdf.
4. Federal Trade Commission. Generic drug entry prior to patent expiration: an FTC Study, July 2002. http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf.
5. Whitehead B., Jackson S., Kempner R. Managing generic competition and patent strategies in the pharmaceutical industry. Journal of Intellectual Property Law & Practice 2008, 10.1093/jiplp/jpn013.
6. Impotence: NIH consensus development panel on impotence. Journal of the American Medical Association 1993, 270:83-90.
7. Khan M.A., Thompson C.S., Sullivan M.E., Jeremy J.Y., Mikhailidis D.P., Morgan R.J. The role of prostaglandins in the etiology and treatment of erectile dysfunction. Prostaglandinstreatment of erectile dysfunction. Prostaglandins. Leukotrienes and Essential Fatty Acids 1999, 60(3):169-174.